# è«–æ–‡ç ”ç©¶æ­·ç¨‹è¨˜éŒ„ (Research Journey)

## ðŸ“‹ å°ˆæ¡ˆåŸºæœ¬è³‡è¨Š
- **è«–æ–‡é¡Œç›®**: An Empirical Comparison of Interpretable and Black-box Models for Predicting Hypertension, Hyperglycemia, and Dyslipidemia
- **ç ”ç©¶ç”Ÿ**: ç´€ä¼¯å–¬ (å­¸è™Ÿ: 21138X006)
- **æŒ‡å°Žæ•™æŽˆ**: è¨±æšæ•™æŽˆ
- **å­¸æ ¡**: åœ‹ç«‹è‡ºåŒ—æ•™è‚²å¤§å­¸ è³‡è¨Šç§‘å­¸ç³» åœ¨è·ç¢©å£«ç­
- **ç ”ç©¶æœŸé–“**: 2024å¹´12æœˆ - 2026å¹´ (é è¨ˆ)

---

## ðŸŽ¯ ç ”ç©¶æ ¸å¿ƒå•é¡Œ
æ¯”è¼ƒ**å¯è§£é‡‹æ¨¡åž‹** (Interpretable Models) èˆ‡**é»‘ç›’æ¨¡åž‹** (Black-box Models) åœ¨ä¸‰é«˜ç–¾ç—…é¢¨éšªé æ¸¬ä¸Šçš„è¡¨ç¾å·®ç•°ï¼ŒæŽ¢è¨Žæº–ç¢ºçŽ‡èˆ‡å¯è§£é‡‹æ€§ä¹‹é–“çš„æ¬Šè¡¡é—œä¿‚ã€‚

### ç›®æ¨™ç–¾ç—… (3H)
1. **é«˜è¡€å£“** (Hypertension): â‰¥140/90 mmHg
2. **é«˜è¡€ç³–** (Hyperglycemia): ç©ºè…¹è¡€ç³– â‰¥126 mg/dL, HbA1c â‰¥6.5%
3. **é«˜è¡€è„‚** (Dyslipidemia): é«˜LDL-C, é«˜TG, ä½ŽHDL

### æ¨¡åž‹æ¯”è¼ƒ
- **å¯è§£é‡‹æ¨¡åž‹**: Logistic Regression, Decision Tree
- **é»‘ç›’æ¨¡åž‹**: Random Forest, SVM, Neural Networks
- **è§£é‡‹æ–¹æ³•**: SHAP, Feature Importance

---

## ðŸ“… ç ”ç©¶é€²å±•æ™‚é–“ç·š

### Phase 1: å°ˆæ¡ˆå¥ åŸºæœŸ (2024å¹´12æœˆ)
**Meeting 01** - å°ˆæ¡ˆå•Ÿå‹•
- ç¢ºç«‹ç ”ç©¶ä¸»é¡Œèˆ‡æ–¹å‘
- å»ºç«‹å®Œæ•´å°ˆæ¡ˆæž¶æ§‹ (RiskPrediction-3H)
- åˆå§‹è³‡æ–™é›†: SUA_CVDs_risk_factors.csv (25,744ç­†è¨˜éŒ„)
- Gitç‰ˆæœ¬æŽ§åˆ¶ç³»çµ±å»ºç«‹

### Phase 2: é ˜åŸŸçŸ¥è­˜å»ºæ§‹æœŸ (2025å¹´1-2æœˆ)
**Meeting 02-03** - Domain Knowledge æ·±åº¦ç ”ç©¶
- åˆ¶å®š6å¤§æž¶æ§‹ç ”ç©¶è¨ˆç•«:
  1. åŸºç¤Žå®šç¾© & è‡¨åºŠè¨ºæ–·æ¨™æº–
  2. ä¸‰é«˜çš„æµè¡Œç—…å­¸èƒŒæ™¯  
  3. è‡¨åºŠèˆ‡ç”Ÿç†é—œè¯
  4. è³‡æ–™ä¾†æºèˆ‡å¸¸è¦‹æŒ‡æ¨™
  5. ç ”ç©¶æ–¹æ³• & æ‡‰ç”¨å ´æ™¯
  6. çˆ­è­°èˆ‡ç ”ç©¶ç©ºç™½

- èˆ‡é†«å¸«å°ˆå®¶è¨Žè«– (2025/01/08)
- ç¢ºç«‹è¨ºæ–·cutoffå€¼æ¨™æº–
- åˆ†æžæ··æ·†è®Šæ•¸èˆ‡è‡¨åºŠå¯¦å‹™å·®ç•°

### Phase 3: æ–¹æ³•è«–è¨­è¨ˆæœŸ (2025å¹´2-4æœˆ)
**Meeting 04-06** - ç ”ç©¶æ–¹æ³•è«–å»ºç«‹
- æŽ¡ç”¨7éšŽæ®µç³»çµ±æ€§ç ”ç©¶æµç¨‹:
  1. Literature Review (2-4é€±)
  2. Research Question & Hypothesis (1é€±)
  3. Data Collection & Understanding (1-2é€±)
  4. Methodology Design (1-2é€±)
  5. Experiments (3-4é€±)
  6. Analysis & Results (2-3é€±)
  7. Paper Writing (4-6é€±)

- ç¢ºç«‹è«–æ–‡å¯«ä½œé †åº: Methods â†’ Results â†’ Discussion â†’ Introduction â†’ Abstract
- é ä¼°ç¸½ç ”ç©¶æ™‚é–“: 22é€± (ç´„5-6å€‹æœˆ)

### Phase 4: å¯¦é©—è¨­è¨ˆå„ªåŒ–æœŸ (2025å¹´5-7æœˆ)
**Meeting 07-10** - è³‡æ–™é›†ç­–ç•¥é‡å¤§èª¿æ•´
- **é—œéµæ±ºç­–**: å¾žå–®ä¸€å¤§åž‹è³‡æ–™é›†è½‰ç‚ºå¤šè³‡æ–™é›†æ¯”è¼ƒé©—è­‰
- æ–°å¢ž4å€‹æ¨™æº–é†«å­¸è³‡æ–™é›†:
  1. **Chronic Kidney Disease (CKD)**: 400ç­†, ä¸å¹³è¡¡æ¯”27:73
  2. **Fertility Diagnosis**: 100ç­†, ä¸å¹³è¡¡æ¯”88:12  
  3. **Wisconsin Diagnostic Breast Cancer (WDBC)**: 569ç­†
  4. **BUPA Liver Disorders**: 345ç­†

**Meeting 10é‡è¦é‡Œç¨‹ç¢‘**:
- å®Œæˆè³‡æ–™é›†æ•´ç†èˆ‡æ–‡æª”åŒ–
- ç¢ºç«‹å¤šè³‡æ–™é›†é©—è­‰ç­–ç•¥
- ç‚ºæ¨¡åž‹é€šç”¨æ€§æ¸¬è©¦å¥ å®šåŸºç¤Ž

### Phase 5: æ¨¡åž‹å¯¦é©—æœŸ (2025å¹´8-9æœˆ)  
**Meeting 11-13** - æ¨¡åž‹æ¯”è¼ƒèˆ‡å¯¦é©—
- æ¨¡åž‹å¯¦ä½œèˆ‡è¨“ç·´
- äº¤å‰é©—è­‰ç­–ç•¥åŸ·è¡Œ
- æ•ˆèƒ½æŒ‡æ¨™åˆ†æž: Accuracy, Precision, Recall, F1-score, ROC-AUC
- SHAPè§£é‡‹æ€§åˆ†æž

---

## ðŸ“š æ–‡ç»ç ”ç©¶èˆ‡é ˜åŸŸçŸ¥è­˜

### 6å¤§é ˜åŸŸçŸ¥è­˜æž¶æ§‹

#### 1. è‡¨åºŠè¨ºæ–·æ¨™æº–ç ”ç©¶
- **é«˜è¡€å£“æ¨™æº–**: å„åœ‹è¨ºæ–·æ¨™æº–å·®ç•°åˆ†æž
- **è¡€ç³–è¨ºæ–·**: ç©ºè…¹è¡€ç³– vs HbA1cçˆ­è­°è¨Žè«–
- **è¡€è„‚æ¨™æº–**: ä¸åŒæ—ç¾¤cutoffå€¼å·®ç•°
- **é—œéµæ´žå¯Ÿ**: è¨ºæ–·æ¨™æº–ç›´æŽ¥å½±éŸ¿æ¨¡åž‹æ¨™è¨»èˆ‡åˆ†é¡žæº–ç¢ºæ€§

#### 2. æµè¡Œç—…å­¸èƒŒæ™¯åˆ†æž
- **è³‡æ–™ä¾†æº**: WHO, NCD-RisC, NHANES
- **ç››è¡ŒçŽ‡è¶¨å‹¢**: å…¨çƒèˆ‡å°ç£/æ±äºžæ¯”è¼ƒ (1975-2020)
- **äººå£å­¸åˆ†å¸ƒ**: å¹´é½¡å±¤ã€æ€§åˆ¥å·®ç•°åˆ†æž
- **ç–¾ç—…è² æ“”**: å…¬å…±è¡›ç”Ÿæ„ç¾©èˆ‡ç ”ç©¶é‡è¦æ€§

#### 3. ç”Ÿç†æ©Ÿåˆ¶èˆ‡å…±ç—…é—œè¯
- **å…±åŒå±éšªå› å­**: è‚¥èƒ–ã€ä»£è¬ç—‡å€™ç¾¤ã€ç”Ÿæ´»ç¿’æ…£
- **äº¤äº’ä½œç”¨**: ä¸‰é«˜ç–¾ç—…é–“çš„åŠ ä¹˜æ•ˆæ‡‰
- **ä½µç™¼ç—‡**: å¿ƒè¡€ç®¡ç–¾ç—…ã€è…Žç—…ã€ä¸­é¢¨é—œè¯
- **ç ”ç©¶gap**: MLæ¨¡åž‹èƒ½å¦æ•æ‰è¤‡é›œäº¤äº’ä½œç”¨

#### 4. è³‡æ–™ç‰¹å¾µèˆ‡æŒ‡æ¨™
- **æ ¸å¿ƒæŒ‡æ¨™**: è¡€å£“ã€è¡€ç³–(FBG, HbA1c)ã€è¡€è„‚(TC, LDL, HDL, TG)
- **è¡ç”ŸæŒ‡æ¨™**: BMI, è…°è‡€æ¯”, GFR, å°¿é…¸
- **å¤§åž‹è³‡æ–™é›†**: Framingham, NHANES, MIMICæ¯”è¼ƒåˆ†æž
- **è³‡æ–™å“è³ª**: ç¼ºå¤±å€¼ã€ç•°å¸¸å€¼ã€æ¸¬é‡æ¨™æº–åŒ–

#### 5. ç ”ç©¶æ–¹æ³•èˆ‡æ‡‰ç”¨å ´æ™¯
- **å‚³çµ±çµ±è¨ˆ**: Cox regression, Logistic regression
- **æ©Ÿå™¨å­¸ç¿’**: ç›£ç£å­¸ç¿’ã€ç‰¹å¾µé¸æ“‡ã€æ¨¡åž‹è©•ä¼°
- **æ·±åº¦å­¸ç¿’**: ç¥žç¶“ç¶²è·¯åœ¨é†«å­¸é æ¸¬çš„æ‡‰ç”¨
- **è‡¨åºŠæ‡‰ç”¨**: é¢¨éšªé æ¸¬å·¥å…·ã€å¥åº·ç®¡ç†ã€æ”¿ç­–åˆ¶å®š

#### 6. ç ”ç©¶çˆ­è­°èˆ‡å‰µæ–°æ©Ÿæœƒ
- **é«˜è¡€å£“**: "æ­£å¸¸é«˜å€¼"ç•Œç·šçˆ­è­° (120-139 mmHg)
- **ç³–å°¿ç—…**: HbA1c vs ç©ºè…¹è¡€ç³–ä¸»å°Žçˆ­è­°
- **è¡€è„‚**: æ—ç¾¤ç‰¹ç•°æ€§cutoffå€¼å•é¡Œ
- **æ¨¡åž‹è§£é‡‹**: æº–ç¢ºæ€§vså¯è§£é‡‹æ€§æ¬Šè¡¡å•é¡Œ

---

## ðŸ”„ é—œéµæ±ºç­–èˆ‡è½‰æŠ˜é»ž

### é‡å¤§ç­–ç•¥èª¿æ•´ (Meeting 10)
**åŽŸå§‹è¨ˆç•«**:
- å–®ä¸€å¤§åž‹å¿ƒè¡€ç®¡è³‡æ–™é›† (25,744ç­†)
- å°ˆæ³¨ä¸‰é«˜ç–¾ç—…é æ¸¬

**èª¿æ•´å¾Œç­–ç•¥**:
- å¤šå€‹æ¨™æº–é†«å­¸è³‡æ–™é›†é©—è­‰
- æ“´å±•åˆ°ä¸åŒé†«å­¸é æ¸¬ä»»å‹™
- æå‡æ¨¡åž‹é€šç”¨æ€§é©—è­‰

**æ±ºç­–ç†ç”±**:
1. å¢žå¼·ç ”ç©¶çµè«–çš„å»£æ³›é©ç”¨æ€§
2. ä½¿ç”¨æ¨™æº–benchmarkè³‡æ–™é›†ä¾¿æ–¼æ¯”è¼ƒ
3. é¿å…å–®ä¸€è³‡æ–™é›†çš„ç‰¹æ®Šæ€§é™åˆ¶
4. æå‡è«–æ–‡ç™¼è¡¨ç«¶çˆ­åŠ›

### ç ”ç©¶æ–¹æ³•è«–æ¼”é€²
**åˆæœŸ**: ç›´è§€çš„å¯¦é©—é©…å‹•æ–¹æ³•
**ç¾åœ¨**: ç³»çµ±æ€§7éšŽæ®µç ”ç©¶æµç¨‹
**æ”¹é€²**: å…ˆæ–‡ç»å›žé¡§å†å¯¦é©—ï¼Œé¿å…ç›²ç›®å˜—è©¦

---

## ðŸ“Š ç•¶å‰ç ”ç©¶ç‹€æ…‹ (2025å¹´9æœˆ)

### å·²å®Œæˆé …ç›® âœ…
- [x] å°ˆæ¡ˆæž¶æ§‹å»ºç«‹èˆ‡ç‰ˆæœ¬æŽ§åˆ¶
- [x] 6å¤§é ˜åŸŸçŸ¥è­˜æž¶æ§‹ç ”ç©¶
- [x] 7éšŽæ®µç ”ç©¶æ–¹æ³•è«–è¨­è¨ˆ
- [x] å¤šè³‡æ–™é›†é¸æ“‡èˆ‡æ–‡æª”åŒ–
- [x] 13æ¬¡æ­£å¼advisor meeting
- [x] è‡¨åºŠå°ˆå®¶è«®è©¢èˆ‡é©—è­‰

### é€²è¡Œä¸­é …ç›® ðŸ”„
- [ ] Literature Reviewæ·±åŒ– (Stage 1/7)
- [ ] æ¨¡åž‹å¯¦é©—èˆ‡æ¯”è¼ƒåˆ†æž
- [ ] SHAPè§£é‡‹æ€§åˆ†æž
- [ ] çµ±è¨ˆé¡¯è‘—æ€§æª¢é©—

### å¾…åŸ·è¡Œé …ç›® ðŸ“‹
- [ ] Research Questionå…·é«”åŒ– (Stage 2)
- [ ] è³‡æ–™æŽ¢ç´¢èˆ‡å‰è™•ç† (Stage 3)
- [ ] å®Œæ•´å¯¦é©—åŸ·è¡Œ (Stage 5)
- [ ] çµæžœåˆ†æžèˆ‡è¨Žè«– (Stage 6)
- [ ] è«–æ–‡æ’°å¯« (Stage 7)

---

## ðŸŽ¯ é æœŸè²¢ç»èˆ‡å½±éŸ¿

### å­¸è¡“è²¢ç»
1. **æ¨¡åž‹æ¯”è¼ƒæ¡†æž¶**: ç³»çµ±æ€§æ¯”è¼ƒå¯è§£é‡‹vsé»‘ç›’æ¨¡åž‹
2. **å¤šè³‡æ–™é›†é©—è­‰**: æå‡çµè«–çš„å»£æ³›é©ç”¨æ€§
3. **è‡¨åºŠå¯è§£é‡‹æ€§**: æ©‹æŽ¥AIæŠ€è¡“èˆ‡é†«ç™‚å¯¦å‹™
4. **è©•ä¼°æ–¹æ³•è«–**: å¹³è¡¡æº–ç¢ºæ€§èˆ‡å¯è§£é‡‹æ€§çš„è©•ä¼°æ¨™æº–

### å¯¦å‹™æ‡‰ç”¨åƒ¹å€¼
1. **è‡¨åºŠæ±ºç­–æ”¯æ´**: å¹«åŠ©é†«å¸«ç†è§£AIé æ¸¬çµæžœ
2. **é¢¨éšªè©•ä¼°å·¥å…·**: ä¸‰é«˜ç–¾ç—…æ—©æœŸç¯©æª¢æ‡‰ç”¨
3. **å¥åº·ç®¡ç†**: å€‹äººåŒ–å¥åº·é¢¨éšªé æ¸¬
4. **æ”¿ç­–åˆ¶å®š**: å…¬å…±è¡›ç”Ÿè³‡æºé…ç½®åƒè€ƒ

---

## ðŸš€ æœªä¾†ç ”ç©¶æ–¹å‘

### çŸ­æœŸç›®æ¨™ (2025å¹´10æœˆ-12æœˆ)
1. å®Œæˆæ–‡ç»å›žé¡§èˆ‡ç ”ç©¶å•é¡Œå…·é«”åŒ–
2. æ·±åº¦è³‡æ–™æŽ¢ç´¢èˆ‡ç‰¹å¾µå·¥ç¨‹
3. æ¨¡åž‹å¯¦ä½œèˆ‡åˆæ­¥å¯¦é©—
4. å»ºç«‹è©•ä¼°æ¡†æž¶èˆ‡åŸºç·šçµæžœ

### ä¸­æœŸç›®æ¨™ (2026å¹´1æœˆ-3æœˆ)
1. å®Œæ•´å¯¦é©—åŸ·è¡Œèˆ‡çµæžœåˆ†æž
2. çµ±è¨ˆæª¢é©—èˆ‡é¡¯è‘—æ€§é©—è­‰
3. SHAPè§£é‡‹æ€§æ·±åº¦åˆ†æž
4. è‡¨åºŠæ„ç¾©è¨Žè«–èˆ‡é©—è­‰

### é•·æœŸç›®æ¨™ (2026å¹´4æœˆ-6æœˆ)
1. è«–æ–‡æ’°å¯«èˆ‡ä¿®è¨‚
2. ç ”ç©¶çµæžœç™¼è¡¨æº–å‚™
3. å¾ŒçºŒç ”ç©¶è¦åŠƒ
4. å¯¦éš›æ‡‰ç”¨ç³»çµ±é–‹ç™¼å¯èƒ½æ€§

---

## ðŸ“ˆ æˆåŠŸæŒ‡æ¨™èˆ‡é‡Œç¨‹ç¢‘

### é‡åŒ–æŒ‡æ¨™
- **æ¨¡åž‹æ•ˆèƒ½**: ROC-AUC > 0.8, F1-score > 0.7
- **çµ±è¨ˆé¡¯è‘—æ€§**: p-value < 0.05
- **è§£é‡‹æ€§è©•ä¼°**: SHAP values analysiså®Œæ•´æ€§
- **è«–æ–‡å“è³ª**: ç¬¦åˆåœ‹éš›æœŸåˆŠç™¼è¡¨æ¨™æº–

### è³ªæ€§æŒ‡æ¨™
- **è‡¨åºŠç›¸é—œæ€§**: é†«å¸«å°ˆå®¶èªå¯èˆ‡é©—è­‰
- **å¯¦ç”¨æ€§**: å¯¦éš›é†«ç™‚ç’°å¢ƒé©ç”¨æ€§
- **å‰µæ–°æ€§**: åœ¨å¯è§£é‡‹AIé†«ç™‚æ‡‰ç”¨çš„è²¢ç»
- **å®Œæ•´æ€§**: ç³»çµ±æ€§ç ”ç©¶æµç¨‹å®Œæ•´åŸ·è¡Œ

---

## ðŸ’¡ ç¶“é©—ç¸½çµèˆ‡æ•™è¨“

### æˆåŠŸç¶“é©—
1. **ç³»çµ±æ€§æ–¹æ³•**: 6+7æž¶æ§‹ç¢ºä¿ç ”ç©¶å®Œæ•´æ€§
2. **å°ˆå®¶è«®è©¢**: è‡¨åºŠé†«å¸«åƒèˆ‡æå‡ç ”ç©¶å“è³ª
3. **æ–‡æª”ç®¡ç†**: å®Œæ•´ç‰ˆæœ¬æŽ§åˆ¶èˆ‡é€²åº¦è¿½è¸ª
4. **æŒçºŒæºé€š**: å®šæœŸadvisor meetingç¢ºä¿æ–¹å‘æ­£ç¢º

### æŒ‘æˆ°èˆ‡æ‡‰å°
1. **è³‡æ–™é›†é¸æ“‡**: å¾žå–®ä¸€åˆ°å¤šå…ƒç­–ç•¥èª¿æ•´
2. **ç ”ç©¶ç¯„åœ**: å¹³è¡¡æ·±åº¦èˆ‡å»£åº¦çš„å–æ¨
3. **æ™‚ç¨‹ç®¡ç†**: ç³»çµ±æ€§æµç¨‹vså¯¦éš›é€²åº¦å”èª¿
4. **æŠ€è¡“è¤‡é›œåº¦**: AIå¯è§£é‡‹æ€§é‡åŒ–è©•ä¼°æŒ‘æˆ°

### é—œéµå­¸ç¿’
1. **å…ˆè¦åŠƒå¾ŒåŸ·è¡Œ**: é¿å…ç›²ç›®å¯¦é©—æµªè²»æ™‚é–“
2. **é ˜åŸŸçŸ¥è­˜é‡è¦æ€§**: domain knowledgeæ±ºå®šç ”ç©¶å“è³ª
3. **æŒçºŒèª¿æ•´ç­–ç•¥**: æ ¹æ“šé€²å±•éˆæ´»èª¿æ•´æ–¹å‘
4. **å®Œæ•´è¨˜éŒ„åƒ¹å€¼**: ç ”ç©¶æ­·ç¨‹æ–‡æª”åŒ–çš„é‡è¦æ€§

---

## ðŸ“š é‡è¦è³‡æºèˆ‡åƒè€ƒ

### ç ”ç©¶å·¥å…·èˆ‡å¹³å°
- **ç‰ˆæœ¬æŽ§åˆ¶**: Git/GitHub
- **é–‹ç™¼ç’°å¢ƒ**: Python, Jupyter Notebooks
- **MLæ¡†æž¶**: scikit-learn, TensorFlow/PyTorch
- **è§£é‡‹å·¥å…·**: SHAP, LIME
- **çµ±è¨ˆåˆ†æž**: SciPy, statsmodels

### é—œéµè³‡æ–™é›†
- **åŽŸå§‹è³‡æ–™**: SUA_CVDs_risk_factors.csv (25,744ç­†)
- **æ¯”è¼ƒè³‡æ–™**: CKD, Fertility, WDBC, BUPA Liver
- **åƒè€ƒè³‡æ–™**: WHO, NHANES, Framingham

### é‡è¦æ–‡ç»è³‡æ–™åº«
- **é†«å­¸**: PubMed, Nature Medicine, JMIR
- **AI/ML**: IEEE Xplore, ICML, NeurIPS
- **è·¨é ˜åŸŸ**: Google Scholar, Artificial Intelligence in Medicine

---

*æœ€å¾Œæ›´æ–°: 2025å¹´9æœˆ9æ—¥*
*ç ”ç©¶ç‹€æ…‹: Literature ReviewéšŽæ®µ (Stage 1/7)*
*é è¨ˆå®Œæˆ: 2026å¹´6æœˆ*